Background: Midlife hypertension followed by late life hypotension resulting from neurodegeneration increases amyloidogenesis and tauopathy. Methods: Consecutive outpatients with late-onset Alzheimer's disease (AD) at various stages and their respective caregivers were assessed for score variations in 1 year of tests assessing caregiver burden, functionality and cognition according to blood pressure (BP) variations and APOE haplotypes, while also taking into account differential effects of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, β-blockers, calcium channel blockers, diuretics, or no antihypertensive medication on score changes. The diagnosis and treatment of arterial hypertension followed the JNC 7 report. Results: Variations in systolic BP (-11.76 ± 17.1 mm Hg), diastolic BP (-4.92 ± 10.3 mm Hg) and pulse pressure (-6.84 ± 12.6 mm Hg) were significant after 1 year (n = 191; ρ < 0.01). For APOE4+ carriers, rises in systolic or diastolic BP improved Clinical Dementia Rating Scale Sum of Boxes scores (ρ < 0.04), with marginally significant improvements in Mini-Mental State Examination scores resulting from risen systolic (ρ = 0.069) or diastolic BP (ρ = 0.079), and in basic independence only regarding risen diastolic BP (ρ = 0.055). APOE4- carriers resisted any functional or cognitive effects of BP variations. No differences were found regarding any antihypertensive class for variations in BP or any test scores, regardless of APOE haplotypes. Conclusions: Targeting mild BP elevations brings better functional and cognitive results for APOE4+ carriers with AD.

Keywords:
Alzheimer’s disease, Cognitive disorders, Dementia, Neurodegenerative diseases, Hypertension, Activities of daily living, Neuropsychiatry, APOE
1.
Feldstein CA: Effects of blood pressure changes on Alzheimer's disease. Neuroepidemiology 2010;35:202-212.
2.
Lattanzi S, Viticchi G, Falsetti L, Buratti L, Luzzi S, Provinciali L, Silvestrini M: Visit-to-visit blood pressure variability in Alzheimer disease. Alzheimer Dis Assoc Disord 2014;28:347-351.
3.
De Oliveira FF, Pivi GAK, Chen ES, Smith MC, Bertolucci PHF: Risk factors for cognitive and functional change in one year in patients with Alzheimer's disease dementia from São Paulo, Brazil. J Neurol Sci 2015;359:127-132.
4.
van Bruchem-Visser RL, Mattace-Raso FUS, van der Cammen TJM: High systolic and pulse pressure levels are associated with better cognitive performance in patients with probable Alzheimer's disease: a cross-sectional observational study in a geriatric outpatient population. Dement Geriatr Cogn Disord 2009;28:320-324.
5.
Szewieczek J, Dulawa J, Francuz T, Legierska K, Hornik B, Włodarczyk-Sporek I, Janusz-Jenczeń M, Batko-Szwaczka A: Mildly elevated blood pressure is a marker for better health status in Polish centenarians. Age (Dordr) 2015;37:9738.
6.
Ganguli M, Fu B, Snitz BE, Unverzagt FW, Loewenstein DA, Hughes TF, Chang CCH: Vascular risk factors and cognitive decline in a population sample. Alzheimer Dis Assoc Disord 2014;28:9-15.
7.
De Oliveira FF, Bertolucci PHF, Chen ES, Smith MC: Risk factors for age at onset of dementia due to Alzheimer's disease in a sample of patients with low mean schooling from São Paulo, Brazil. Int J Geriatr Psychiatry 2014;29:1033-1039.
8.
Oliveira FF, Machado FC, Sampaio G, Marin SMC, Chen ES, Smith MC, Bertolucci PHF: Contrasts between patients with Lewy body dementia syndromes and APOE-ε3/ε3 patients with late-onset Alzheimer disease dementia. Neurologist 2015;20:35-41.
9.
Lattanzi S, Luzzi S, Provinciali L, Silvestrini M: Blood pressure variability predicts cognitive decline in Alzheimer's disease patients. Neurobiol Aging 2014;35:2282-2287.
10.
Keary TA, Gunstad J, Poppas A, Paul RH, Jefferson AL, Hoth KF, Sweet LH, Forman DE, Cohen RA: Blood pressure variability and Dementia Rating Scale performance in older adults with cardiovascular disease. Cogn Behav Neurol 2007;20:73-77.
11.
Forlenza OV, Diniz BS, Talib LL, Radanovic M, Yassuda MS, Ojopi EB, Gattaz WF: Clinical and biological predictors of Alzheimer's disease in patients with amnestic mild cognitive impairment. Rev Bras Psiquiatr 2010;32:216-222.
12.
Wattmo C, Londos E, Minthon L: Risk factors that affect life expectancy in Alzheimer's disease: a 15-year follow-up. Dement Geriatr Cogn Disord 2014;38:286-299.
13.
Strand BH, Rosness TA, Engedal K, Magnus P, Bergem ALM, Schirmer H, Bjertness E, Knudsen GP: Interaction of apolipoprotein E genotypes, lifestyle factors and future risk of dementia-related mortality: the Cohort of Norway (CONOR). Dement Geriatr Cogn Disord 2015;40:137-147.
14.
Allan CL, Ebmeier KP: The influence of ApoE4 on clinical progression of dementia: a meta-analysis. Int J Geriatr Psychiatry 2011;26:520-526.
15.
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carillo MC, Thies B, Weintraub S, Phelps CH: The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimerʼs disease. Alzheimers Dement 2011;7:263-269.
16.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ: The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560-2572.
17.
American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2006;29 (suppl 1):S43-S48.
18.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
19.
Folstein MF, Folstein S, McHugh PR: Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
20.
Freedman M, Leach L, Kaplan E, Winocur G, Shulman KI, Delis DC: Clock Drawing: A Neuropsychological Analysis. New York, Oxford University Press, 1994.
21.
Chaves MLF, Camozzato AL, Godinho C, Kochhann R, Schuh A, Almeida VL, Kaye J: Validity of the Clinical Dementia Rating scale for the detection and staging of dementia in Brazilian patients. Alzheimer Dis Assoc Disord 2007;21:210-217.
22.
Katz S, Akpom CA: A measure of primary socio-biological functions. Int J Health Serv 1976;6:493-508.
23.
Lawton MP: Instrumental Activities of Daily Living (IADL) Scale: self-reported version. Psychopharmacol Bull 1988;24:789-791.
24.
Taub A, Andreoli SB, Bertolucci PHF: Dementia caregiver burden: reliability of the Brazilian version of the Zarit Caregiver Burden Interview. Cad Saude Publica 2004;20:372-376.
25.
De Oliveira FF, Wajman JR, Bertolucci PHF, Chen ES, Smith MC: Correlations among cognitive and behavioural assessments in patients with dementia due to Alzheimer's disease. Clin Neurol Neurosurg 2015;135:27-33.
26.
Blom K, Emmelot-Vonk MH, Koek HDL: The influence of vascular risk factors on cognitive decline in patients with dementia: a systematic review. Maturitas 2013;76:113-117.
27.
Abellan van Kan G, Rolland Y, Nourhashémi F, Coley N, Andrieu S, Vellas B: Cardiovascular disease risk factors and progression of Alzheimer's disease. Dement Geriatr Cogn Disord 2009;27:240-246.
28.
Qiao J, Lu WH, Wang J, Guo XJ, Qu QM: Vascular risk factors aggravate the progression of Alzheimer's disease: a 3-year follow-up study of Chinese population. Am J Alzheimers Dis Other Demen 2014;29:521-525.
29.
Glodzik L, Rusinek H, Pirraglia E, McHugh P, Tsui W, Williams S, Cummings M, Li Y, Rich K, Randall C, Mosconi L, Osorio R, Murray J, Zetterberg H, Blennow K, de Leon M: Blood pressure decrease correlates with tau pathology and memory decline in hypertensive elderly. Neurobiol Aging 2014;35:64-71.
30.
Stewart R, Xue QL, Masaki K, Petrovitch H, Ross GW, White LR, Launer LJ: Change in blood pressure and incident dementia: a 32-year prospective study. Hypertension 2009;54:233-240.
31.
Nation DA, Edmonds EC, Bangen KJ, Delano-Wood L, Scanlon BK, Han SD, Edland SD, Salmon DP, Galasko DR, Bondi MW: Pulse pressure in relation to tau-mediated neurodegeneration, cerebral amyloidosis, and progression to dementia in very old adults. JAMA Neurol 2015;72:546-553.
32.
Razay G, Williams J, King E, Smith AD, Wilcock G: Blood pressure, dementia and Alzheimer's disease: the OPTIMA longitudinal study. Dement Geriatr Cogn Disord 2009;28:70-74.
33.
De Oliveira FF, Bertolucci PHF, Chen ES, Smith MC: Brain-penetrating angiotensin-converting enzyme inhibitors and cognitive change in patients with dementia due to Alzheimer's disease. J Alzheimers Dis 2014;42 (suppl 3):S321-S324.
34.
Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B: Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010;340:b5465.
35.
Yasar S, Xia J, Yao W, Furberg CD, Xue QL, Mercado CI, Fitzpatrick AL, Fried LP, Kawas CH, Sink KM, Williamson JD, DeKosky ST, Carlson MC; Ginkgo Evaluation of Memory (GEM) Study Investigators: Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study. Neurology 2013;81:896-903.
36.
Wharton W, Goldstein FC, Zhao L, Steenland K, Levey AI, Hajjar I: Modulation of renin-angiotensin system may slow conversion from mild cognitive impairment to Alzheimer's disease. J Am Geriatr Soc 2015;63:1749-1756.
37.
De Oliveira FF, Bertolucci PHF, Chen ES, Smith MAC: Pharmacological modulation of cognitive and behavioral symptoms in patients with dementia due to Alzheimer's disease. J Neurol Sci 2014;336:103-108.
38.
De Oliveira FF, Wajman JR, Bertolucci PHF: Caregiver awareness of cerebrovascular risk of patients with dementia due to Alzheimer's disease in São Paulo, Brazil. Rev Psiquiatr Clin 2014;41:77-81.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.